Imcyse, a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases, recently announced that it has raised €35 million ($39.5M) in a Series B financing round and through other channels.
The financing round of €28 million ($31.6M) in equity was led by LSP together with Belgian investors including Epimède, the Société Régionale d’Investissement de Wallonie (SRIW), and the Société Fédérale de Participations et d’Investissement (SFPI). Existing shareholders (Biogenosis, Noshaq, KU Leuven) also participated in the round.